The FDA has approved new indications for the atypical antipsychotic drug lurasidone (Latuda; Sunovion) in treatment of patients with depressive episodes associated with bipolar I disorder. The approval covers use alone and as adjunctive therapy with lithium or valproate.
Lurasidone was already approved for use in patients with schizophrenia.
With the new indications, the drug appeared to cause fewer metabolic problems or weight gain than other drugs in its class.
–Psychiatric News Alert